Stocks Health care LLY
NYSE · Health careELI LILLY & Co (LLY)
ELI LILLY & Co brought in $86.5B of revenue over the twelve months to September 30, 2026, up 45.5% from a year earlier. Net income was $27.6B, a net margin of 31.9%. At September 30, 2026 it held $4.9B in cash against $47B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about ELI LILLY & Co
- Net worth
- ELI LILLY & Co has a market value (market cap) of $1.35T at the latest share price, and shareholders' equity of $40.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $65.2B (+44.7% year on year), with net income of $20.6B. Over the 12 months to September 30, 2026: revenue $86.5B, net income $27.6B.
- Cash flow
- In fiscal 2025 operations brought in $16.8B of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- ELI LILLY & Co's next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- ELI LILLY & Co declared dividends of $6.23 per share in fiscal 2025, a yield of 0.43% at the current price.
What ELI LILLY & Co does
Eli Lilly and Company is a pharmaceutical company that discovers, develops, and sells prescription medicines. It produces treatments for diabetes, obesity, oncology, immunology, and neuroscience conditions. Its products are purchased by wholesalers, pharmacies, hospitals, and healthcare providers. The company is known for drugs such as Prozac, Humalog, and Mounjaro. Its shares trade on NYSE under the ticker LLY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $65.2B | $20.6B | $22.95 | n/a |
| 2024 | $45B | $10.6B | $11.71 | n/a |
| 2023 | $34.1B | $5.2B | $5.80 | n/a |
| 2022 | $28.5B | $6.2B | $6.90 | n/a |
| 2021 | $28.3B | $5.6B | $6.12 | n/a |
| 2020 | $24.5B | $6.2B | $6.79 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LLY ranks in Health care
Dividends
ELI LILLY & Co declared $6.23 per share in fiscal 2025. At the current price that is a yield of 0.43%. It paid out $5.4B in cash dividends, 26% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $6.23 | $5.4B | 26% |
| 2024 | $5.40 | $4.7B | 44% |
| 2023 | $4.69 | $4.1B | 78% |
| 2022 | $4.07 | $3.5B | 57% |
| 2021 | $3.53 | $3.1B | 55% |
| 2020 | $3.07 | $2.7B | 43% |
Latest SEC filings
What ELI LILLY & Co has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 39% to $24.4B versus the same quarter last year; diluted EPS $7.22 versus $6.21.
- October 29, 2026
- October 19, 2026Passive stake changed SCHEDULE 13G/A
- October 16, 2026Activist stake (5% or more) SCHEDULE 13D
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 48% to $23B versus the same quarter last year; diluted EPS $7.94 versus $6.29.
- August 5, 2026
- July 30, 2026Activist stake (5% or more) SCHEDULE 13D
- July 24, 2026Passive stake changed SCHEDULE 13G/A
- July 24, 2026Passive stake (5% or more) SCHEDULE 13G
- July 23, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running ELI LILLY & Co did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $14.7M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Ricks David APresident, Chair, and CEO, Director | Gave as a gift | 23,538 | - |
| November 2, 2026 | Hakim AnatEVP, GC & Secretary | Soldpre-planned (10b5-1), indirect | 5,000 | $7M |
| November 2, 2026 | Skovronsky DanielEVP, CS&PO & Pres. LRL | Gave as a gift | 119 | - |
| November 1, 2026 | Montarce LucasEVP & CFO | Exercised options | 1,610 | - |
| November 1, 2026 | Montarce LucasEVP & CFO | Shares withheld for tax | 678 | $960.5K |
| November 1, 2026 | Hernandez EdgardoEVP & Pres., Mfg. Operations | Exercised options | 2,530 | - |
| November 1, 2026 | Hernandez EdgardoEVP & Pres., Mfg. Operations | Shares withheld for tax | 1,123 | $1.6M |
| November 1, 2026 | Dozier EricEVP, Chief People Officer | Exercised options | 2,300 | - |
Who owns LLY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lilly Endowment, Inc.13G, passive | 9.6% | July 23, 2026 |
| ELI LILLY & Co13D, may seek influence | 7.3% | July 30, 2026 |
| Vanguard Capital Management13G, passive | 6.48% | May 1, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 4,619 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Lilly Endowment Inc | 90,376,978 | -1,520,000 |
| BlackRock, Inc. | 67,540,400 | +1,159,558 |
| Vanguard Capital Management LLC | 53,528,868 | +167,094 |
| PNC Financial Services Group, Inc. | 51,322,720 | -6,188 |
| State Street Corp | 36,215,754 | +605,752 |
| Fmr LLC | 28,462,475 | +2,121,444 |
| Capital Research Global Investors | 20,873,140 | -3,759,507 |
| Vanguard Portfolio Management LLC | 20,859,217 | -117,810 |
| Geode Capital Management, LLC | 20,310,858 | +118,994 |
| Morgan Stanley | 16,226,398 | +788,940 |
| Capital World Investors | 15,902,642 | +280,829 |
| Jpmorgan Chase & Co | 12,598,524 | -1,099,967 |
| Norges Bank | 11,471,413 | new |
| Bank of America Corp | 11,274,243 | +148,411 |
| Wellington Management Group Llp | 10,998,953 | -2,428,108 |
| State Farm Mutual Automobile Insurance Co | 10,759,188 | 0 |
| Primecap Management Co | 9,172,904 | -50,528 |
| Northern Trust Corp | 8,796,866 | -30,698 |
| Goldman Sachs Group Inc | 7,652,960 | +1,312,095 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 7,209,385 | +137,364 |
Insiders
25 insiders reported holding 93,077,248 shares in total, about $133.31B at the last price.
| Holder | Shares |
|---|---|
| Lilly Endowment IncFormer 10% Shareholder | 91,881,150 |
| Ricks David APresident, Chair, and CEO, Director | 555,278 |
| Skovronsky DanielEVP, CS&PO & Pres. LRL | 159,953 |
| Fyrwald J ErikDirector | 75,544 |
| Alvarez RalphDirector | 55,848 |
| Jonsson PatrikEVP & President, LLY Int'l | 54,147 |
| Hernandez EdgardoEVP & Pres., Mfg. Operations | 47,490 |
| Yuffa IlyaEVP&Pres, LLY USA&Global Capab | 29,804 |
| Hakim AnatEVP, GC & Secretary | 27,1244,137 held indirectly |
| Van Naarden JacobEVP,Pres LLY Oncology&HdCorpBD | 26,626 |
Questions about LLY
What does ELI LILLY & Co do?
Eli Lilly and Company is a pharmaceutical company that discovers, develops, and sells prescription medicines. It produces treatments for diabetes, obesity, oncology, immunology, and neuroscience conditions. Its products are purchased by wholesalers, pharmacies, hospitals, and healthcare providers. The company is known for drugs such as Prozac, Humalog, and Mounjaro. Its shares trade on NYSE under the ticker LLY.
What is ELI LILLY & Co's net worth?
ELI LILLY & Co has a market value (market cap) of $1.35T at the latest share price, and shareholders' equity of $40.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is ELI LILLY & Co profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $27.6B on revenue of $86.5B, a net margin of 31.9%.
How much revenue does ELI LILLY & Co make?
Over the twelve months to September 30, 2026 ELI LILLY & Co reported revenue of $86.5B. That is 45.5% more than a year earlier.
When did ELI LILLY & Co last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is ELI LILLY & Co's next earnings report?
ELI LILLY & Co's next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Does ELI LILLY & Co pay a dividend?
Yes. ELI LILLY & Co declared dividends of $6.23 per share in fiscal 2025, a yield of 0.43% at the current price.
Similar companies
Compare LLY with
Follow LLY
Get an email when ELI LILLY & Co files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values ELI LILLY & Co tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.